Press release
Hormone Refractory Prostate Cancer Market Estimated to Flourish by 2016 – 2024
Hormone refractory prostate Cancer (HRPC) is also known as Castrate-Resistant Prostate Cancer (CRPC). It is a peculiar type of cancer which relapses even after hormonal therapy. Now a days it has been categorized under prostate cancer. Hormone Refractory Prostate Cancer (HRPCA) or Castrate-Resistant Prostate Cancer (CRPC) is a type of prostate cancer that recurs after having hormonal therapy. Due to the high unmet clinical need associated with limited survival periods, intensifying HRPCA prevalence and fast-emerging treatment modifications, the global HRPCA market is poised to witness an unprecedented growth. Mostly prostate cancers are found during screening with a digital rectal exam or prostate-specific antigen blood test. Initially prostate cancers usually don’t show any symptoms, but on advancing cancer stages are sometimes symptoms can be seen. If Hormone Refractory Prostate Cancer is suspected based on the outcomes of screening tests or symptoms, tests are needed to confirm the diagnosis. The definite diagnosis of prostate cancer can be done with a prostate biopsy.Request to View Tables of Content @ http://www.persistencemarketresearch.com/toc/12748
The driving factors for Hormone Refractory Prostate cancer market are promising pipeline drugs, evolving patterns of treatment, augmented with patient awareness. Larger untapped pool of patients from Asia Pacific region would opt for the treatment of Hormone Refractory Prostate Cancer which will boost the sales revenue in the market. On the other hand premium prices drugs for Hormone Refractory Prostate Cancer, indeterminate reimbursement policies and limited period of survival would hinder the growth of the market over the forecast period. Physicians being reluctant towards promoting and adopting premium would acts as a key challenge in the growth of market players. Whereas untapped patient population with non-metastatic Hormone Refractory Prostate Cancer from emerging countries would open new avenues for the new and existing players. This undiagnosed patient population and mounting prevalence would provide growth opportunities in future.
The global Hormone Refractory Prostate Cancer market is segmented on the basis of type of therapy and end user type
Based on type of therapy, the global Hormone Refractory Prostate Cancer market is segmented into the following
Chemotherapy
Cytotoxic Agents
Hormonal Therapy
Anti-Androgens
Immunotherapy
Radiation Therapy
Surgery
Based on the type of end user, the global Hormone Refractory Prostate Cancer market is segmented into the following
Hospitals
Ambulatory Surgical Centers
Specialty Clinics
Based on treatment type, global Hormone Refractory Prostate Cancer market is classified as chemotherapy, radiation therapy, surgery, immunotherapy, and hormonal therapy. Surgery is expected to lead the global market for prostate cancer over the forecast period as it is the choice of therapy by physicians. Radiation therapy is used to prevent the recurrence of cancer and is expected to contribute second largest share in the global Hormone Refractory Prostate Cancer market. Chemotherapy is used as an adjunct to other therapies and thus hold little share in global Hormone Refractory Prostate Cancer market.
Based on end user, global Hormone Refractory Prostate Cancer market has been segmented into hospitals, ambulatory surgical centers and specialty clinics. Hospital end user type segment is expected to contribute the highest share in the global market for global Hormone refractory prostate cancer market.
Based on the regional presence, global Hormone Refractory Prostate Cancer market is segmented into five key regions viz. North America, Latin America, Europe, Asia-Pacific, and the Middle East & Africa. North America will continue to dominate the global Hormone Refractory Prostate Cancer market for due to high prevalence which are diagnosed with advanced technology. It is one of the most common type of malignancy which is observed amongst men in United States and is the second largest cause of Cancer deaths in United States. Europe is expected to hold second largest market share in global Hormone Refractory Prostate Cancer market. Followed by Europe the other regions like Asia Pacific, MEA and Latin America which has a large pool of undiagnosed Hormone Refractory Prostate Cancer would continue to grow with increasing awareness and advanced screening technology.
Some of the key players competing in hormone refractory prostate cancer market include AbbVie Inc., Acceleron Pharma, Inc., AB Science SA, AstraZeneca Plc., Astellas Pharma Inc., Bayer AG, Boston Biomedical, Inc., Bristol-Myers Squibb Company and others.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, types, technology and applications.
The report covers exhaustive analysis on:
Market Segments
Market Dynamics
Market Size
Supply & Demand
Current Trends/Issues/Challenges
Competition & Companies involved
Technology
Value Chain
Regional analysis includes
North America (U.S., Canada)
Latin America (Argentina, Mexico, Brazil, Rest of Latin America)
Europe (Germany, Italy, France, U.K., Spain, Russia, Rest of Europe)
Asia Pacific (China, India, Japan, Rest of APAC)
Middle East and Africa (Rest of MEA, S. Africa)
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
To view complete report @ http://www.persistencemarketresearch.com/market-research/hormone-refractory-prostate-cancer-market.asp
About Us
Persistence Market Research (PMR) is a U.S.-based full-service market intelligence firm specializing in syndicated research, custom research, and consulting services. PMR boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients’ business needs.
PMR stands committed to bringing more accuracy and speed to clients’ business decisions. From ready-to-purchase market research reports to customized research solutions, PMR’s engagement models are highly flexible without compromising on its deep-seated research values.
Contact
Persistence Market Research Pvt. Ltd
305 Broadway
7th Floor, New York City,
NY 10007, United States,
USA – Canada Toll Free: 800-961-0353
Email: sales@persistencemarketresearch.com
media@persistencemarketresearch.com
Web:www.persistencemarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hormone Refractory Prostate Cancer Market Estimated to Flourish by 2016 – 2024 here
News-ID: 640239 • Views: …
More Releases from Persistence Market Research

North America Wiring Devices Market Projected to Reach USD 26.46 Billion by 2031
Overview of the North America Wiring Devices Market
The North America wiring devices market is poised for steady growth over the forecast period, with its size estimated at US$ 18.96 billion in 2024, projected to reach US$ 26.46 billion by 2031, reflecting a CAGR of 4.9%. The market is witnessing substantial expansion due to increasing urbanization, a rising number of residential and commercial construction projects, and the adoption of energy-efficient and…

Global Forged Automotive Components Market Poised for Steady Growth, Projected t …
The global forged automotive components market is on a robust growth trajectory, currently valued at approximately US$ 50.3 billion in 2025 and forecasted to expand to US$ 70.7 billion by the end of 2032. This growth represents a compound annual growth rate (CAGR) of 5.0% over the coming decade, driven by increasing automotive production, technological advancements, and evolving consumer preferences toward durable, high-performance vehicle parts.
Forged automotive components are critical to…

Global Electric Cargo Bike Market Set to Accelerate at 11.9% CAGR, Reaching US$ …
The global electric cargo bike market is set to experience substantial growth over the coming decade, with Persistence Market Research (PMR) forecasting a compound annual growth rate (CAGR) of 11.9% from 2023 through 2032. Valued at approximately US$ 800 million in 2021, the market is expected to surge to a projected valuation of US$ 2.14 billion by the end of 2032. Notably, electric cargo bikes accounted for 66.2% of the…

Bicycle Bearings Market Set for Steady Growth with 6.5% CAGR Through 2032, Drive …
The global bicycle bearings market is poised for significant expansion over the forecast period of 2025 to 2032, according to the latest report released by Persistence Market Research. Valued at approximately US$ 5.99 billion in 2024, the market is projected to reach US$ 6.35 billion by 2025 and further escalate to nearly US$ 9.86 billion by 2032. This growth trajectory reflects a compound annual growth rate (CAGR) of 6.5%, underscoring…
More Releases for Cancer
Cancer Therapeutics Market New Business Opportunities to Hit $180.19 billion by …
Surge in geriatric population and rise in the number of collaborations & partnerships to facilitate drug development are the key drivers of the global cancer therapeutics market. In addition, heavy inflow of investment in R&D activities has enhanced the development of cancer therapeutics. Furthermore, favorable government regulations for cancer therapeutics and surge in cancer prevalence boost the market. The high demand for personalized medicine along with high potential of emerging…
Global Cancer Diagnostics Market Size, Trends & Growth Opportunity By Applicatio …
Cancer diagnostics is a process of detecting various proteins, biomarkers and certain symptoms that result in the detection of presence of cancerous tumour in patients. Detection of certain proteins and biomarkers which are prevalent in cancer disorder thereby results in diagnosis process. Cancer diagnostics includes usage of certain technology and devices for detection purpose.
Increase in incidence of target diseases like cancer is key driving factor which is expected to boost…
2019-2027 Oncology Nutrition Market is driven by Major Cancer Type - Head and Ne …
The "Global Oncology Nutrition Market Analysis to 2027" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of oncology nutrition market with detailed market segmentation by cancer type and geography. The global oncology nutrition market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the…
Cancer Immunotherapy Market 2018 To 2025 - SWOT Analysis By Global Industry Reve …
The Cancer Immunotherapy Market research report provided by Crystal Market Research (CMR) is the most detailed study about Cancer Immunotherapy Market that is estimated to grow at a tremendous rate over the forecast period 2018-2025. This report contains precise and updated insights in respect with the leading market players and prevailing regions of the business.
Cancer Immunotherapy Market By Product and Cancer Type - Global Industry Analysis And Forecast To 2025:…
Oncology Nutrition Market by Cancer Type Breast Cancer, Liver Cancer, Lung Cance …
Lunch of new products for nutrition of oncology patients is expected to drive the oncology nutrition market growth. For instance, in 2016, Hormel Food Corporation, a U.S-based meat food products company, launched a line of packaged ready-to-eat meals for cancer patients, which are called as Hormel Vital Cuisine.
These meals consist of carbohydrates, proteins, and fats to help patients fight loss of muscle mass and energy during cancer treatment. Thus launch…
Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung …
Researchmoz added Most up-to-date research on "Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung Cancer, Kidney Cancer, Bone Cancer, Breast Cancer, Prostate Cancer, And Others" to its huge collection of research reports.
Tumor ablation is the removal of the tumor cells or tissue with minimally invasive procedure. Tumor ablation devices are consists of an applicator (catheter), which is introduced into the tumor under imaging guidance. For…